- Home
- PYPL vs GSK Comparison
PYPL vs GSK Comparison
Compare PYPL & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$61.63
HOLD
Current Price
$48.85
Company Overview
Basic Information| Metric | PYPL | GSK |
|---|---|---|
| Founded | 1998 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7B | 95.3B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | PYPL | GSK |
|---|---|---|
| Price | $61.63 | $48.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 28 | 1 |
| Target Price | ★ $80.13 | N/A |
| AVG Volume (30 Days) | ★ 16.2M | 4.2M |
| Earning Date | 10-28-2025 | 10-29-2025 |
| Dividend Yield | 0.91% | ★ 3.40% |
| EPS Growth | 18.59 | ★ 118.57 |
| EPS | ★ 4.98 | 1.79 |
| Revenue | $32,862,000,000.00 | ★ $43,237,357,842.00 |
| Revenue This Year | $6.91 | $6.56 |
| Revenue Next Year | $6.06 | $5.13 |
| P/E Ratio | ★ $12.38 | $13.25 |
| Revenue Growth | ★ 4.47 | 2.73 |
| 52 Week Low | $55.85 | $31.72 |
| 52 Week High | $93.25 | $49.31 |
Technical Indicators
Market Signals| Indicator | PYPL | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 43.99 | 60.04 |
| Support Level | $59.85 | $47.20 |
| Resistance Level | $62.94 | $49.31 |
| Average True Range (ATR) | 1.49 | 0.61 |
| MACD | 0.26 | -0.04 |
| Stochastic Oscillator | 43.51 | 81.02 |
Price Performance
Historical Comparison PYPL
GSK
About PYPL PayPal Holdings Inc.
PayPal was spun off from eBay in 2015 and provides electronic payment solutions to merchants and consumers, with a focus on online transactions. The company had 434 million active accounts at the end of 2024. The company also owns Venmo, a person-to-person payment platform.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.